United States: SEC Steps Up Investigations Of Political Intelligence Firms For Insider Trading

In the last few years, Congress, the U.S. Securities and Exchange Commission (SEC), and the courts have significantly increased their efforts to grapple with insider trading in the realm of political intelligence. In 2012, Congress enacted the Stop Trading on Congressional Knowledge Act (STOCK Act), which explicitly applies federal insider trading laws to legislative branch employees. In the wake of the passage of the STOCK Act, the SEC has initiated at least one high-profile investigation involving the distribution of political intelligence about an unexpected increase in Medicare reimbursements to institutional fund clients (the Sutter Investigation). We have previously reported on that investigation1.This week, the SEC announced the culmination of another, similar investigation of Marwood Group Research LLC (Marwood). The breadth of the Sutter and the Marwood Investigations, combined with the passage of the STOCK Act, suggests a concerted effort by Congress and the SEC to prosecute insider trading in political intelligence on a much broader scale than had previously been pursued. Political intelligence firms and institutional funds that obtain political intelligence as part of their trading strategies should be aware of this focus, and review their compliance policies accordingly.

The SEC's Marwood Investigation

Marwood is a registered broker-dealer and investment adviser, which provides regulatory and government intelligence updates (called "research notes") to clients, including hedge funds. According to the SEC, in two separate instances in 2010 Marwood analysts learned from federal employees about potential non-public developments in health care regulations and then shared this intelligence with clients without ensuring that it did not qualify as material non-public information (MNPI).2 Even though Marwood had written compliance policies and procedures requiring employees to verify that any intelligence was not based on MNPI, in both cases, the firm's employees failed to identify the potential MNPI and failed to consult with the compliance department.

In the first incident, a Marwood employee who had previously worked at the Centers for Medicare and Medicaid Services (CMS) allegedly learned from former colleagues that the CMS had commenced an investigation into Medicare coverage of the immunotherapy drug Provenge (to determine whether it was "reasonable and necessary" for the diagnosis or treatment of a specific illness or injury) because of concerns about unapproved use of the drug. The Marwood employee was told that the intelligence was "good color," but he was also warned that if he leaked the information he would get "locked out of any conversations going forward." Despite the warning, no one at Marwood consulted with the compliance department, and analysts disseminated research notes speculating that the CMS would continue covering Provenge for on-label uses.

In the second incident, a Marwood consultant who was formerly with the U.S. Food and Drug Administration (FDA) allegedly learned from his former colleagues that the agency was concerned about safety issues with a potential new diabetes drug called Bydureon. Again, without consulting compliance, the firm told various clients that the FDA might deny the drug's application.

Marwood was charged with violations under Section 15(g) of the Exchange Act of 1934 (Exchange Act) and Section 204A of the Investment Advisers Act of 1940 ( Investment Advisers Act). Marwood agreed to settle the charges, and, as part of the settlement, consented to a cease and desist order, agreed to pay a fine of $375,000, and admitted wrong doing – i.e., that the firm failed to establish, maintain, and enforce written policies and procedures requiring employees to verify that the health care intelligence was not MNPI. The firm also agreed to hire an independent consultant to improve its compliance protocols.

The Marwood Investigation also follows on the heels of — but is different than — other SEC investigations of insider trading based on confidential information held by the FDA about the status of particular drug approvals or the results of clinical trials. Previous cases involving FDA-confidential information, such as the SEC's widely publicized enforcement action against FDA chemist Cheng Yi Liang and his son, involved more traditional fact patterns where clearly confidential FDA information was misappropriated in order to conduct unlawful trading.3 By contrast, in the Marwood investigation, the information from the CMS and the FDA was much more akin to the type of information frequently gathered by political information firms on background and then disseminated to their institutional fund clientele. Clearly, the SEC is stepping up its enforcement efforts against trading on "political" information, even when it does not directly bring charges of insider trading.

Lessons From the SEC's Political Intelligence Enforcement Efforts

There are a number of lessons from the SEC's recent investigations involving political intelligence firms:

1. Insider Trading Charges Involving Political Intelligence are Hard to Prosecute

The SEC did not charge Marwood with an actual violation of the insider trading laws under Section 10(b) of the Exchange Act. The SEC Order carefully refers to the health care intelligence as "potential" MNPI, but never alleges that the intelligence in question actually was MNPI. As we have previously noted, the application of insider trading concepts to the legislative and executive agency sphere raises a number of important issues unique to that realm:

What, exactly, is "non-public" information taken "in breach of a duty of trust or confidence," in the inherently public (as opposed to private) sphere of elected or appointed officials?

What type of "benefit," exactly, does the recent decision in United States v. Newman require be shown when the currency of trade in the public sector differs so markedly from that in the private sector?

Even before Newman, the potential prosecution of insider trading charges involving political information was problematic; in the wake of Newman, the challenges become even more pointed.

2. In the Absence of Insider Trading Charges, the SEC Will Prosecute Compliance Process Failures

In 2010, Marwood already had written policies and procedures that most firms would likely consider sufficient, including a requirement that a supervisor review all regulatory and legislative research notes and a requirement that, if there is "any doubt" as to whether the information was MNPI, the employee must refrain from disseminating the information and contact compliance. According to the SEC, however, Marwood's policies were inadequate because 1) They "did not expressly require the compliance department to be advised as to the source of the information included in the research note or about communications with government sources, if any," and 2) Marwood's managers failed reasonably to enforce the existing policy because they should have quarantined potential MNPI and sought guidance from compliance. The SEC also confirmed what it had previously determined in similar situations, that where a broker-dealer or investment adviser has employees who might come into possession of MNPI on a regular basis, a general policy requiring the employees to self-evaluate the information, without more protocols, is insufficient to comply with Section 15(g) of the Exchange Act and Section 204A of the Investment Advisers Act.

In the wake of Marwood, political intelligence firms should again take a close look at their written policies and procedures concerning MNPI, perhaps even requiring compliance to review all political intelligence prior to dissemination and requiring supervisors to become more active in terms of quarantining potential MNPI. Again, perhaps in light of the difficulties in prosecuting exchanges of potential MNPI in the political intelligence realm the SEC's current solution is not to provide more guidance about what constitutes MNPI but to emphasize the necessity of adopting internal policies which require employees in political intelligence firms to defer more to the compliance departments.

3. Political Intelligence Firms May Be Prosecuted Under Rules Specific to Broker-Dealers and Investment Advisers

Some political intelligence firms do not register as broker-dealers or investment advisers; Marwood did. While the SEC could use a variety of tools (including the insider trading laws) to prosecute unlawful "tipping" by political intelligence firms and their sources, in Marwood's case the agency ultimately decided to rest its action — as it frequently does — on violations of the compliance and supervision requirements for broker-dealers and investment advisers.

4. The SEC Has Robust Discovery Tools in Its Toolbox to Prosecute Political Intelligence Firms

As with any investigation, the SEC enjoys a broad range of discovery tools when investigating political intelligence firms — including electronic market surveillance, document subpoenas, and the ability to take testimony under oath — which are not available to the firms being investigated.

Recently, at least one court has held that such subpoenas can include documents prepared or received by the legislative branch. In the Sutter Investigation, the Committee on Ways and Means of the U.S. House of Representatives and Brian Sutter refused to respond to the SEC's investigative subpoenas, arguing that the information was protected from disclosure in discovery under the doctrine of sovereign immunity and under the Constitution's Speech and Debate Clause. The court rejected these defenses; and in particular found that Congress had waived its sovereign immunity by passing the STOCK Act. See supra n.1.

With these latest investigative salvos, the SEC not only continues to make inroads into a new realm of MNPI within the world of political intelligence, but also continues to carry a number of enforcement tools in its arsenal to pursue this new path.


1 More recently, the United States District Court for the Southern District of New York held that the SEC is not prevented from seeking information from Congressional sources. SEC v. Comm. on Ways & Means of the United States House of Representatives, 14 Misc. 193 (PGG), 2015 U.S. Dist. LEXIS 154302 (S.D.N.Y. Nov. 13, 2015).

2 SEC Order, In the Matter of Marwood Group Research LLC, Release Nos. 34-76512, 40-4279, Adm. Proc. File No. 3-16970 (Nov. 24, 2015), https://www.sec.gov/litigation/admin/2015/34-76512.pdf.

3 FDA Chemist and Son Charged with Trading on Inside Information, DOJ Press Release No. 11-393 (Mar. 29, 2011), http://www.justice.gov/opa/pr/fda-chemist-and-son-charged-trading-inside-information ; SEC Charges FDA Chemist With Insider Trading Ahead of Drug Approval Announcements, SEC Press Release No. 2011-76 (Mar. 29, 2011), http://www.sec.gov/news/press/2011/2011-76.htm; see also SEC Charges Two Clinical Drug Trial Doctors With Insider Trading, SEC Press Release No. 2014-100 (May 19, 2014), http://www.sec.gov/News/PressRelease/Detail/PressRelease/1370541857556.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.